[go: up one dir, main page]

TR200003787A2 - Kararlı yavaş salımlı oral dozaj bileşimi. - Google Patents

Kararlı yavaş salımlı oral dozaj bileşimi.

Info

Publication number
TR200003787A2
TR200003787A2 TR2000/03787A TR200003787A TR200003787A2 TR 200003787 A2 TR200003787 A2 TR 200003787A2 TR 2000/03787 A TR2000/03787 A TR 2000/03787A TR 200003787 A TR200003787 A TR 200003787A TR 200003787 A2 TR200003787 A2 TR 200003787A2
Authority
TR
Turkey
Prior art keywords
oral dosage
allergic
dosage composition
allergic rhinitis
symptoms
Prior art date
Application number
TR2000/03787A
Other languages
English (en)
Other versions
TR200003787A3 (tr
Inventor
H. Kou Jim
Original Assignee
Schering Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22629437&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR200003787(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corporation filed Critical Schering Corporation
Publication of TR200003787A3 publication Critical patent/TR200003787A3/tr
Publication of TR200003787A2 publication Critical patent/TR200003787A2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Toys (AREA)
  • Cosmetics (AREA)

Abstract

Bu bulus film kapli yavas salimli kati oral dozaj bilesimine iliskin olup, kontrollü salimli bir çekirdek içinde bir nazal dekonjestan, örnegin psödoefedrin ve sakinlestirici etkisi olmayan antihistamin, desloratadin ihtiva eden bir film dis kaplama ihtiva eder. Bu bulusa mahsus kati oral dozaj bilesimleri, alerjik ve /veya enflamatuvar durumarda, örnegin soguk alginligi ile baglantili belirti ve semptomlar ve ayrica deri veya üst ve alt solunum yollarinin alerjik ve/veya enflamatuvar durumlari, örnegin alerjik rinit, mevsimsel alerjik rinit ve nazal konjesyo, üst solunum yollari hastaliklari, alerjik rinit ve nazal konjesyon ile baglantili belirti ve semptomlar gösteren hastalarin tedavisi için faydalidir.
TR2000/03787A 1999-12-20 2000-12-20 Kararlı yavaş salımlı oral dozaj bileşimi. TR200003787A2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17283699P 1999-12-20 1999-12-20

Publications (2)

Publication Number Publication Date
TR200003787A3 TR200003787A3 (tr) 2001-07-23
TR200003787A2 true TR200003787A2 (tr) 2001-07-23

Family

ID=22629437

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/03787A TR200003787A2 (tr) 1999-12-20 2000-12-20 Kararlı yavaş salımlı oral dozaj bileşimi.

Country Status (37)

Country Link
US (2) US6979463B2 (tr)
EP (2) EP1112738B1 (tr)
JP (3) JP5042403B2 (tr)
KR (2) KR100936572B1 (tr)
CN (3) CN101081224B (tr)
AR (1) AR027033A1 (tr)
AT (1) ATE463240T1 (tr)
AU (4) AU2277101A (tr)
BR (1) BR0006403A (tr)
CA (1) CA2329217C (tr)
CO (1) CO5251435A1 (tr)
CY (1) CY1110693T1 (tr)
CZ (1) CZ302860B6 (tr)
DE (1) DE60044117D1 (tr)
DK (1) DK1112738T3 (tr)
EC (1) ECSP003836A (tr)
EG (1) EG23759A (tr)
ES (1) ES2341751T3 (tr)
HU (1) HUP0004988A3 (tr)
ID (1) ID28675A (tr)
IL (1) IL140450A (tr)
MX (1) MXPA00013037A (tr)
MY (1) MY130773A (tr)
NO (1) NO331645B1 (tr)
NZ (1) NZ509028A (tr)
PE (1) PE20010982A1 (tr)
PL (1) PL211573B1 (tr)
PT (1) PT1112738E (tr)
RU (2) RU2303440C2 (tr)
SA (2) SA06270069B1 (tr)
SG (1) SG109438A1 (tr)
SI (1) SI1112738T1 (tr)
SK (1) SK287684B6 (tr)
TR (1) TR200003787A2 (tr)
TW (1) TWI225414B (tr)
WO (1) WO2001045668A2 (tr)
ZA (1) ZA200007715B (tr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001045676A2 (en) 1999-12-20 2001-06-28 Schering Corporation Extended release oral dosage composition
AU2277101A (en) 1999-12-20 2001-07-03 Schering Corporation Stable extended release oral dosage composition
US7405223B2 (en) 2000-02-03 2008-07-29 Schering Corporation Treating allergic and inflammatory conditions
US20030070584A1 (en) 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing cellulose ethers
CN1518448A (zh) * 2001-06-20 2004-08-04 ���鹫˾ 用于治疗鼻充血和鼻塞的抗组胺剂
US8309118B2 (en) 2001-09-28 2012-11-13 Mcneil-Ppc, Inc. Film forming compositions containing sucralose
US8323692B2 (en) 2002-02-21 2012-12-04 Valeant International Bermuda Controlled release dosage forms
NZ535455A (en) * 2002-02-21 2009-08-28 Biovail Lab Int Srl Controlled release dosage forms
WO2004080461A2 (en) * 2003-03-12 2004-09-23 TEVA Gyógyszergyár Részvénytársaság Stable pharmaceutical compositions of desloratadine
US20050013863A1 (en) 2003-07-18 2005-01-20 Depomed, Inc., A Corporation Of The State Of California Dual drug dosage forms with improved separation of drugs
US20070116764A1 (en) * 2003-12-01 2007-05-24 Shigeyuki Marunaka Method for treatment of solid pharmaceutical preparation prior to printing and solid pharmaceutical preparation subjected to treatment prior to printing
US20060110449A1 (en) * 2004-10-25 2006-05-25 Lorber Richard R Pharmaceutical composition
US20060252831A1 (en) * 2005-05-06 2006-11-09 Christopher Offen Method for the treatment of magnesium and potassium deficiencies
US20060252830A1 (en) * 2005-05-06 2006-11-09 Brandon Stephen F Method for the treatment of magnesium and potassium deficiencies
US20070014855A1 (en) * 2005-07-12 2007-01-18 Rahul Gawande S Stable desloratadine compositions
US20070036859A1 (en) * 2005-08-11 2007-02-15 Perry Ronald L Sustained release antihistamine and decongestant composition
US7827042B2 (en) 2005-11-30 2010-11-02 The Invention Science Fund I, Inc Methods and systems related to transmission of nutraceutical associated information
US8000981B2 (en) 2005-11-30 2011-08-16 The Invention Science Fund I, Llc Methods and systems related to receiving nutraceutical associated information
US10296720B2 (en) 2005-11-30 2019-05-21 Gearbox Llc Computational systems and methods related to nutraceuticals
US7927787B2 (en) 2006-06-28 2011-04-19 The Invention Science Fund I, Llc Methods and systems for analysis of nutraceutical associated components
US7974856B2 (en) 2005-11-30 2011-07-05 The Invention Science Fund I, Llc Computational systems and methods related to nutraceuticals
US20080210748A1 (en) 2005-11-30 2008-09-04 Searete Llc, A Limited Liability Corporation Of The State Of Delaware, Systems and methods for receiving pathogen related information and responding
US8297028B2 (en) 2006-06-14 2012-10-30 The Invention Science Fund I, Llc Individualized pharmaceutical selection and packaging
US8340944B2 (en) 2005-11-30 2012-12-25 The Invention Science Fund I, Llc Computational and/or control systems and methods related to nutraceutical agent selection and dosing
FR2894143B1 (fr) * 2005-12-01 2008-05-02 Pierre Fabre Medicament Sa Composition a liberation prolongee de l'actif, son procede de preparation et son utilisation.
WO2007143158A2 (en) * 2006-06-01 2007-12-13 Schering-Plough Healthcare Products, Inc. Sustained release pharmaceutical formulation comprising phenylephrine
NZ573174A (en) * 2006-06-01 2012-01-12 Msd Consumer Care Inc Sustained release pharmaceutical dosage form containing phenylephrine
CN101472561A (zh) * 2006-06-01 2009-07-01 先灵公司 去氧肾上腺素脉冲释放制剂和药物组合物
BRPI0711871A2 (pt) * 2006-06-01 2011-12-06 Schering Corp composições farmacêuticas para liberação sustentada de fenilefrina
JP2009543780A (ja) * 2006-07-11 2009-12-10 ミューチュアル ファーマシューティカル カンパニー，インク． 制御放出製剤およびキット
EP2164472A1 (en) * 2007-06-01 2010-03-24 Schering-Plough Healthcare Products, Inc. Pharmaceutical composition comprising a substrate and a coating containing an active ingredient and polyvinylalcohol
PE20091084A1 (es) * 2007-12-07 2009-07-23 Schering Plough Healthcare Formulaciones farmaceuticas de fenilefrina y composiciones para absorcion transmucosal
US20120065221A1 (en) 2009-02-26 2012-03-15 Theraquest Biosciences, Inc. Extended Release Oral Pharmaceutical Compositions of 3-Hydroxy-N-Methylmorphinan and Method of Use
WO2010143202A1 (en) * 2009-06-09 2010-12-16 Sun Pharmaceutical Industries Ltd. Pharmaceutical composition
TR201009396A2 (tr) 2010-11-11 2012-05-21 Bi̇lgi̇ç Mahmut Desloratadin granüller
DE102016107760B4 (de) * 2016-04-26 2018-09-20 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Essbare Funktionsschichten und Überzüge auf Hybridpolymerbasis für Pharmazie und Lebensmittel
US20180187263A1 (en) 2017-01-05 2018-07-05 Iowa State University Research Foundation, Inc. Kits for diagnostic detection and prevention of feedlot bovine respiratory disease
WO2022023463A1 (en) 2020-07-30 2022-02-03 Faes Farma, S.A. Decongestant drug delivery system

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US100000A (en) 1870-02-22 Improved sun-bonnet for horses
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3940485A (en) 1973-12-12 1976-02-24 Levinson Harold N Treatment and pre-treatment of dysmetric dyslexia by improving sequential scanning and ocular fixation abilities and therapeutic compounds
US4008796A (en) 1974-03-26 1977-02-22 General Concrete Of Canada Limited Control method for feeding items on a conveyor
GB1548022A (en) 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
US4282233B1 (en) 1980-06-19 2000-09-05 Schering Corp Antihistaminic 11-(4-piperidylidene)-5h-benzoÄ5,6Ü-cyclohepta-Ä1,2Ü-pyridines
HU194864B (en) 1984-02-15 1988-03-28 Schering Corp Process for production of 8-chlor-6,11-dihydro-11-(4-piperidilidene)-5h-benzo (5,6)-cyclo-hepta (1,2-b) pyridine and its salts
US4552899A (en) 1984-04-09 1985-11-12 Analgesic Associates Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs
US4783465A (en) 1984-04-09 1988-11-08 Analgesic Associates Cough/cold mixtures comprising non-sedating antihistamine drugs
SE8404467D0 (sv) 1984-09-06 1984-09-06 Ferrosan Ab Controlled-release medical preparations
US4731447A (en) 1985-05-13 1988-03-15 Schering Corporation Process for preparing piperidylidene dihydro-dibenzo(a,d)-cycloheptenes or aza-derivatives thereof
US4804666A (en) 1985-08-14 1989-02-14 Schering Corporation Antiallergic 6,11-dihydro-11-(4-piperidylidene)-5H-benzo(5,6)cyclohepta(1,2-B)pyridines
JPS6396126A (ja) 1986-10-13 1988-04-27 Taisho Pharmaceut Co Ltd 安定化組成物
US5089496A (en) 1986-10-31 1992-02-18 Schering Corporation Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies
US4777170A (en) 1987-02-03 1988-10-11 Heinrich William A Method to prevent and treat the signs and symptoms of motion sickness
GB8707421D0 (en) * 1987-03-27 1987-04-29 Wellcome Found Pharmaceutical formulations
US4863931A (en) 1988-09-15 1989-09-05 Schering Corporation Antihistaminic fluoro substituted benzocycloheptapyridines
US5019591A (en) 1989-02-17 1991-05-28 Pennsylvania Research Corporation Method for treating retinopathy and other small vessel disorders associated with diabetes
US4990535A (en) 1989-05-03 1991-02-05 Schering Corporation Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine
NZ238629A (en) 1990-06-22 1993-09-27 Schering Corp Bis-benzo- or benzopyrido-cyclohepta (where z is c, o, s or n) piperidine, piperidylidene or piperazine compounds, medicaments and methods of preparation
WO1992011034A1 (en) 1990-12-18 1992-07-09 The Wellcome Foundation Limited Agents for potentiating the effects of antitumor agents and combating multiple drug resistance
PT100502A (pt) 1991-05-20 1993-08-31 Alza Corp Composicoes farmaceuticas para aumentar a capacidade de permeacao na pele utilizando monolinoleato de glicerol
YU48263B (sh) 1991-06-17 1997-09-30 Byk Gulden Lomberg Chemische Fabrik Gmbh. Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola
US5266331A (en) 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
IL104192A (en) * 1992-02-17 1998-01-04 Siegfried Ag Pharma Pharmaceutical dosage forms having prolonged release rate of zero order of the active ingredient
ES2042421B1 (es) 1992-05-22 1994-08-01 Uriach & Cia Sa J Procedimiento para la obtencion de la 8-cloro-11-*1-*(5-metil-3-piridil)metil*-4-piperidiliden*-6,11-dihidro-5h-benzo*5,6*ciclohepta*1,2-b*piridina.
US5314697A (en) 1992-10-23 1994-05-24 Schering Corporation Stable extended release oral dosage composition comprising loratadine and pseudoephedrine
IT1264517B1 (it) 1993-05-31 1996-09-24 Ekita Investments Nv Compressa farmaceutica atta al rilascio in tempi successivi dei principi attivi in essa veicolati
JP2646972B2 (ja) 1993-11-01 1997-08-27 日本電気株式会社 多ビットメモリ
DE4442999A1 (de) 1994-12-02 1996-06-05 Hexal Pharma Gmbh Pharmazeutische Zusammensetzung mit einem aktiven Loratidin-Metaboliten
US5595997A (en) 1994-12-30 1997-01-21 Sepracor Inc. Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine
US5807579A (en) * 1995-11-16 1998-09-15 F.H. Faulding & Co. Limited Pseudoephedrine combination pharmaceutical compositions
JP3220373B2 (ja) * 1995-11-28 2001-10-22 バイエル薬品株式会社 持続性ニフエジピン製剤
NZ335078A (en) * 1996-10-31 2000-10-27 Schering Corp Composition, for the treatment of asthma, containing loratadine and a decongestant
PE71699A1 (es) * 1997-02-07 1999-08-03 Sepracor Inc Composicion farmaceutica de descarboetoxiloratadina sin lactosa, no higroscopica y anhidra
US5900421A (en) 1997-02-11 1999-05-04 Sepracor Inc. Methods and compositions for treating allergic asthma and dermatitis using descarboethoxyloratadine
US5939426A (en) 1997-02-28 1999-08-17 Sepracor Inc. Methods for treating urinary incontinence using descarboethoxyloratadine
US6506767B1 (en) 1997-07-02 2003-01-14 Schering Corporation 8-chloro-6,11-dihydro-11-(4-piperidylidine)-5H-benzo[5,6]cyclohepta[1-2-b] pyridine
US6270796B1 (en) 1997-10-29 2001-08-07 Robert E. Weinstein Antihistamine/decongestant regimens for treating rhinitis
US6132758A (en) 1998-06-01 2000-10-17 Schering Corporation Stabilized antihistamine syrup
CN1145485C (zh) 1998-07-10 2004-04-14 先灵公司 8-氯-6,11-二氢-11-(4-亚哌啶基)-5H-苯并[5,6]环庚三烯并[1,2-b]吡啶口服组合物
US6423721B1 (en) 1998-09-10 2002-07-23 Schering Corporation Methods and compositions for treating sinusitis, otitis media and other related disorders using antihistamines
US6521254B2 (en) 1998-12-07 2003-02-18 J-Med Pharmaceuticals, Inc. Single-dose antihistamine/decongestant formulations for treating rhinitis
US6051585A (en) 1998-12-07 2000-04-18 Weinstein; Robert E. Single-dose antihistamine/decongestant formulations for treating rhinitis
US6100274A (en) 1999-07-07 2000-08-08 Schering Corporation 8-chloro-6,11-dihydro-11- ](4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine oral compositions
US6114346A (en) * 1999-10-22 2000-09-05 Schering Corporation Treating sleep disorders using desloratadine
AU2277101A (en) 1999-12-20 2001-07-03 Schering Corporation Stable extended release oral dosage composition
WO2001045676A2 (en) 1999-12-20 2001-06-28 Schering Corporation Extended release oral dosage composition
US7405223B2 (en) 2000-02-03 2008-07-29 Schering Corporation Treating allergic and inflammatory conditions
AR028502A1 (es) 2000-02-03 2003-05-14 Schering Corp Tratamiento de condiciones inflamatorias alérgicas
US6372802B2 (en) 2000-05-19 2002-04-16 Alcon Universal Ltd. Aniline disulfide derivatives for treating allergic diseases
US6599913B1 (en) 2001-06-29 2003-07-29 Schering Corporation Treating allergic and inflammatory conditions

Also Published As

Publication number Publication date
RU2423106C9 (ru) 2012-06-27
BR0006403A (pt) 2001-07-17
WO2001045668A3 (en) 2001-12-13
AU2009200460B2 (en) 2012-01-19
IL140450A0 (en) 2002-02-10
JP2001172174A (ja) 2001-06-26
CZ20004812A3 (cs) 2001-08-15
NO331645B1 (no) 2012-02-13
CN101081224A (zh) 2007-12-05
AU7244300A (en) 2001-06-21
HK1034453A1 (en) 2001-10-26
JP2008081510A (ja) 2008-04-10
EP1112738A3 (en) 2001-07-18
KR100936572B1 (ko) 2010-01-13
JP5042403B2 (ja) 2012-10-03
KR20110028326A (ko) 2011-03-17
TR200003787A3 (tr) 2001-07-23
DE60044117D1 (de) 2010-05-20
SK19672000A3 (sk) 2001-09-11
SA01210741A (ar) 2005-12-03
AU781924B2 (en) 2005-06-23
SI1112738T1 (sl) 2010-07-30
AU2009200460A1 (en) 2009-02-26
NO20006504L (no) 2001-06-21
WO2001045668A2 (en) 2001-06-28
CZ302860B6 (cs) 2011-12-21
TWI225414B (en) 2004-12-21
US7820199B2 (en) 2010-10-26
ECSP003836A (es) 2002-02-25
PE20010982A1 (es) 2001-09-28
PT1112738E (pt) 2010-06-04
SA06270069B1 (ar) 2009-06-07
CN1679569A (zh) 2005-10-12
AU2277101A (en) 2001-07-03
EP2196195A3 (en) 2012-02-29
HUP0004988A3 (en) 2008-04-28
CN1211079C (zh) 2005-07-20
PL211573B1 (pl) 2012-05-31
HUP0004988A2 (hu) 2002-11-28
PL344715A1 (en) 2001-07-02
CA2329217C (en) 2006-10-31
DK1112738T3 (da) 2010-06-28
SK287684B6 (sk) 2011-06-06
CO5251435A1 (es) 2003-02-28
CN101081224B (zh) 2012-05-30
CA2329217A1 (en) 2001-06-20
RU2007104095A (ru) 2008-08-10
SG109438A1 (en) 2005-03-30
JP2012224642A (ja) 2012-11-15
ES2341751T3 (es) 2010-06-28
ZA200007715B (en) 2001-06-20
AR027033A1 (es) 2003-03-12
US20060159761A1 (en) 2006-07-20
HU0004988D0 (tr) 2001-02-28
NZ509028A (en) 2002-12-20
RU2423106C2 (ru) 2011-07-10
CN1301534A (zh) 2001-07-04
ATE463240T1 (de) 2010-04-15
NO20006504D0 (no) 2000-12-20
ID28675A (id) 2001-06-21
KR20010062542A (ko) 2001-07-07
US6979463B2 (en) 2005-12-27
EP1112738B1 (en) 2010-04-07
IL140450A (en) 2011-11-30
EP2196195A2 (en) 2010-06-16
EG23759A (en) 2007-08-08
CY1110693T1 (el) 2015-06-10
KR101234940B1 (ko) 2013-02-19
US20030086971A1 (en) 2003-05-08
EP1112738A2 (en) 2001-07-04
AU2005203771A1 (en) 2005-09-15
RU2303440C2 (ru) 2007-07-27
MY130773A (en) 2007-07-31
MXPA00013037A (es) 2003-06-19
SA01210741B1 (ar) 2006-10-31

Similar Documents

Publication Publication Date Title
TR200003787A2 (tr) Kararlı yavaş salımlı oral dozaj bileşimi.
Bauer et al. Assessment of preemptive analgesia with ibuprofen coadministered or not with dexamethasone in third molar surgery: a randomized double-blind controlled clinical trial
NO951527D0 (no) Stabilt, oralt doseringspreparat med forlenget frigivelse
FR15C0009I2 (fr) Compositions de gel phospholipide destinees a l'administration medicamenteuse et des methodes de traitement utilisant celles-ci
EP1765379A4 (en) PHARMACEUTICAL CO-CRYSTAL COMPOSITIONS AND RELEVANT USE METHOD
ATE374601T1 (de) Multipartikuläre arzneiform, enthaltend mucoadhaesiv formulierte peptid- oder protein- wirkstoffe, sowie ein verfahren zur herstellung der arzneiform
BR0010498A (pt) Composições modernas de medicamentos à base de compostos anticolinergicamente ativos e beta-miméticos
Rathbone et al. Overview of oral mucosal delivery
CU23468B7 (es) Forma de dosificación de pramipexol en una dosis única diaria
BR9814378A (pt) Forma de dosagem de liberação prolongada farmacêutica revestida entérica de um inibidor de h+, k+-atpase, processos para a manufatura da mesma, para melhorar a inibição de secreção de ácido gástrico, para melhorar o efeito terapêutico no tratamento de distúrbios gastrointentinais, para receber um perfil de plasma prolongado de um inibidor da h+, k+-atpase, e, usos de uma composição farmacêutica e de inibidor da h+, k+-atpase
AR031822A1 (es) Composiciones farmaceuticas que contienen un inhibidor de cox-ii y un relajante muscular.
BR0207883A (pt) Composições de medicamentos à base de anticolenérgicos e inibidores de pde-iv
BR0014312A (pt) Combinação de loteprednol e anti-histaminas
US6521254B2 (en) Single-dose antihistamine/decongestant formulations for treating rhinitis
SG152257A1 (en) Topical preparation containing ambroxol
Spiegel et al. Dysphonia related to medical therapy
Sato et al. Lafutidine, a novel histamine H2-receptor antagonist, increases serum calcitonin gene-related peptide in rats after water immersion-restraint stress
Hanken et al. Basic measures and systemic medical treatment of patients with toxic epidermal necrolysis
AU2000242484B2 (en) Single-dose antihistamine/decongestant formulations for treating rhinitis
DE60321025D1 (de) Verwendung von tenatoprazol zur behandlung von gastroösophogalem reflux
Montes et al. Safety and tolerability of olanzapine compared with other antipsychotics in the treatment of elderly patients with schizophrenia: a naturalistic study
TR200301552A1 (tr) Rofekoksib' in yeni oral farmakolojik formülasyonları.
Ciudad et al. Safety and tolerability of olanzapine compared with other antipsychotics in the treatment of elderly patients with schizophrenia: a naturalistic study
Young ULCERS
UA59359C2 (uk) Фармацевтична композиція та спосіб лікування астми, алергії та запалення у пацієнта